Biotech

PharmaGap Completes $231,000 Private Placement

OTTAWA, ONTARIO: ...

NuPathe Announces Allowance of Additional U.S. Patent Application for Its Migraine Patch

CONSHOHOCKEN, PA: ...

Aptalis Pharma Announces FDA Approval of NDA for Oral Powder Formulation of Viread(R), Co-Developed With Gilead Sciences, Inc.

BRIDGEWATER, NJ: ...

American Pharmaceutical Review Announces Launch of Redesigned Website

SOUTH SAN FRANCISCO, CA: Redesign Strengthens Resource for Pharmaceutical Professionals and Drives Value for Advertisers ...

Miraculins Files with Health Canada for PreVu Medical Device License

WINNIPEG, MANITOBA: ...

Medivation and Pfizer Announce Results From Phase 3 Concert Trial of Dimebon in Alzheimer's Disease

SAN FRANCISCO, CA and NEW YORK, NY: Dimebon Did Not Meet Primary Efficacy Endpoints ...

Cellceutix Anti-Cancer Drug Shown to Regulate HDAC2, a Major Therapeutic Target for Treatment of a Broad Range of Cancers

BEVERLY, MA: Potent Anticancer Activity Demonstrated in a Wide Range of Tumor Types as Kevetrin(TM) Targets a Histone Deacetylase ...

Helix BioPharma Corp. Announces Q1 2012 Results

AURORA, ON: ...

Bioanalytical Systems to Present at the Noble Financial Eighth Annual Equity Conference, Wednesday, January 18, at 1:00 p.m. EST

WEST LAFAYETTE, IN: ...

Portola's J.P. Morgan Healthcare Conference Presentation Focused on Three Transformational Programs for 2012

SOUTH SAN FRANCISCO, CA: Oral Factor Xa Inhibitor Betrixaban to Start Phase 3 Trial; Oral Syk-Specific Kinase Inhibitor to Start Phase 2 Trial; Novel Recombinant Factor Xa Inhibitor Antidote to Start Phase 1 Trial; Portola in ...